-
Chen F, Zhu Y, Wu M, Ku X, Ye S, Li Z, Guo X, He Q, 2015: Comparative genomic analysis of classical and variant virulent parental/attenuated strains of porcine epidemic diarrhea virus[J]. Viruses, 7, 5525-5538. doi: 10.3390/v7102891
-
Choudhury B, Dastjerdi A, Doyle N, Frossard JP, Steinbach F, 2016: From the field to the lab-an European view on the global spread of PEDV[J]. Virus Res, 226, 40-49. doi: 10.1016/j.virusres.2016.09.003
-
Congreve M, Carr R, Murray C, Jhoti H, 2003: A 'Rule of Three' for fragment-based lead discovery?[J]. Drug Discov Today, 8, 876-877. doi: 10.1016/S1359-6446(03)02831-9
-
Cui J, Li F, Shi ZL, 2019: Origin and evolution of pathogenic coronaviruses[J]. Nat Rev Microbiol, 17, 181-192. doi: 10.1038/s41579-018-0118-9
-
Gerdts V, Zakhartchouk A, 2017: Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses[J]. Vet Microbiol, 206, 45-51. doi: 10.1016/j.vetmic.2016.11.029
-
Ghosh AK, Xi K, Ratia K, Santarsiero BD, Fu W, Harcourt BH, Rota PA, Baker SC, Johnson ME, Mesecar AD, 2005: Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors[J]. J Med Chem, 48, 6767-6771. doi: 10.1021/jm050548m
-
Grum-Tokars V, Ratia K, Begaye A, Baker SC, Mesecar AD, 2008: Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery[J]. Virus Res, 133, 63-73. doi: 10.1016/j.virusres.2007.02.015
-
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y, 2020: The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status[J]. Mil Med Res, 7, 11-. doi: 10.1186/s40779-020-00240-0
-
Hofmann M, Wyler R, 1988: Propagation of the virus of porcine epidemic diarrhea in cell culture[J]. J Clin Microbiol, 26, 2235-2239. doi: 10.1128/jcm.26.11.2235-2239.1988
-
Jo S, Kim S, Shin DH, Kim MS, 2020: Inhibition of SARS-CoV 3CL protease by flavonoids[J]. J Enzyme Inhib Med Chem, 35, 145-151. doi: 10.1080/14756366.2019.1690480
-
Jung K, Saif LJ, 2015: Porcine epidemic diarrhea virus infection: Etiology, epidemiology, pathogenesis and immunoprophylaxis[J]. Vet J, 204, 134-143. doi: 10.1016/j.tvjl.2015.02.017
-
Kankanamalage ACG, Kim Y, Damalanka VC, Rathnayake AD, Fehr AR, Mehzabeen N, Battaile KP, Lovell S, Lushington GH, Perlman S, Chang KO, Groutas WC, 2018: Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element[J]. Eur J Med Chem, 150, 334-346. doi: 10.1016/j.ejmech.2018.03.004
-
Kim Y, Mandadapu SR, Groutas WC, Chang KO, 2013: Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease[J]. Antiviral Res, 97, 161-168. doi: 10.1016/j.antiviral.2012.11.005
-
Kim Y, Liu H, Kankanamalage ACG, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC, 2016: Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor[J]. PLoS Pathog, 12, e1005531-. doi: 10.1371/journal.ppat.1005531
-
Kipar A, Meli ML, 2014: Feline infectious peritonitis: still an enigma?[J]. Vet Pathol, 51, 505-526. doi: 10.1177/0300985814522077
-
Kumar V, Shin JS, Shie JJ, Ku KB, Kim C, Go YY, Huang KF, Kim M, Liang PH, 2017: Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitors[J]. Antiviral Res, 141, 101-106. doi: 10.1016/j.antiviral.2017.02.007
-
Langel SN, Paim FC, Lager KM, Vlasova AN, Saif LJ, 2016: Lactogenic immunity and vaccines for porcine epidemic diarrhea virus (PEDV): historical and current concepts[J]. Virus Res, 226, 93-107. doi: 10.1016/j.virusres.2016.05.016
-
Li W, Li H, Liu Y, Pan Y, Deng F, Song Y, Tang X, He Q, 2012: New variants of porcine epidemic diarrhea virus, China, 2011[J]. Emerg Infect Dis, 18, 1350-1353. doi: 10.3201/eid1803.120002
-
Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti AM, Goedhals D, Matthews PC, 2018: A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action[J]. PLoS Negl Trop Dis, 12, e0006629-. doi: 10.1371/journal.pntd.0006629
-
Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S, 2018: Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil[J]. Sci Rep, 8, 9633-. doi: 10.1038/s41598-018-27890-4
-
Pedersen NC, 2009: A review of feline infectious peritonitis virus infection: 1963-2008[J]. J Feline Med Surg, 11, 225-258. doi: 10.1016/j.jfms.2008.09.008
-
Pedersen NC, 2014: An update on feline infectious peritonitis: diagnostics and therapeutics[J]. Vet J, 201, 133-141. doi: 10.1016/j.tvjl.2014.04.016
-
Pensaert MB, de Bouck P, 1978: A new coronavirus-like particle associated with diarrhea in swine[J]. Arch Virol, 58, 243-247. doi: 10.1007/BF01317606
-
Pensaert MB, Martelli P, 2016: Porcine epidemic diarrhea: a retrospect from Europe and matters of debate[J]. Virus Res, 226, 1-6. doi: 10.1016/j.virusres.2016.05.030
-
Perera KD, Kankanamalage ACG, Rathnayake AD, Honeyfield A, Groutas W, Chang KO, Kim Y, 2018: Protease inhibitors broadly effective against feline, ferret and mink coronaviruses[J]. Antiviral Res, 160, 79-86. doi: 10.1016/j.antiviral.2018.10.015
-
Perera KD, Rathnayake AD, Liu H, Pedersen NC, Groutas WC, Chang KO, Kim Y, 2019: Characterization of amino acid substitutions in feline coronavirus 3C-like protease from a cat with feline infectious peritonitis treated with a protease inhibitor[J]. Vet Microbiol, 237, 108398-. doi: 10.1016/j.vetmic.2019.108398
-
Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, Stellberger T, von Dall'Armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, Züst R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Wessels C, Pöhlmann S, Haas J, Drosten C, von Brunn A, 2011: The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors[J]. PLoS Pathog, 7, e1002331-. doi: 10.1371/journal.ppat.1002331
-
Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH, 2016: An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy[J]. J Med Chem, 59, 6595-6628. doi: 10.1021/acs.jmedchem.5b01461
-
Ryu YB, Jeong HJ, Kim JH, Kim YM, Park JY, Kim D, Nguyen TT, Park SJ, Chang JS, Park KH, Rho MC, Lee WS, 2010: Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition[J]. Bioorg Med Chem, 18, 7940-7947. doi: 10.1016/j.bmc.2010.09.035
-
Schoeman D, Fielding BC, 2019: Coronavirus envelope protein: current knowledge[J]. Virol J, 16, 69-. doi: 10.1186/s12985-019-1182-0
-
Shi Y, Li Y, Lei Y, Ye G, Shen Z, Sun L, Luo R, Wang D, Fu ZF, Xiao S, Peng G, 2016: A dimerization-dependent mechanism drives the endoribonuclease function of porcine reproductive and respiratory syndrome virus nsp11[J]. J Virol, 90, 4579-4592. doi: 10.1128/JVI.03065-15
-
Shie JJ, Fang JM, Kuo TH, Kuo CJ, Liang PH, Huang HJ, Wu YT, Jan JT, Cheng YS, Wong CH, 2005: Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha, beta-unsaturated esters[J]. Bioorg Med Chem, 13, 5240-5252. doi: 10.1016/j.bmc.2005.05.065
-
St John SE, Tomar S, Stauffer SR, Mesecar AD, 2015: Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4-The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS)[J]. Bioorg Med Chem, 23, 6036-6048. doi: 10.1016/j.bmc.2015.06.039
-
Stobart CC, Lee AS, Lu X, Denison MR, 2012: Temperature-sensitive mutants and revertants in the coronavirus nonstructural protein 5 protease (3CLpro) define residues involved in long-distance communication and regulation of protease activity[J]. J Virol, 86, 4801-4810. doi: 10.1128/JVI.06754-11
-
Theerawatanasirikul S, Kuo CJ, Phetcharat N, Lekcharoensuk P, 2020: In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus[J]. Antiviral Res, 174, 104697-. doi: 10.1016/j.antiviral.2019.104697
-
Wang D, Fang L, Xiao S, 2016: Porcine epidemic diarrhea in China[J]. Virus Res, 226, 7-13. doi: 10.1016/j.virusres.2016.05.026
-
Wang Q, Vlasova AN, Kenney SP, Saif LJ, 2019: Emerging and re-emerging coronaviruses in pigs[J]. Curr Opin Virol, 34, 39-49. doi: 10.1016/j.coviro.2018.12.001
-
Wood EN, 1977: An apparently new syndrome of porcine epidemic diarrhoea[J]. Vet Rec, 100, 243-244. doi: 10.1136/vr.100.12.243
-
Xie W, Ao C, Yang Y, Liu Y, Liang R, Zeng Z, Ye G, Xiao S, Fu ZF, Dong W, Peng G, 2019: Two critical N-terminal epitopes of the nucleocapsid protein contribute to the cross-reactivity between porcine epidemic diarrhea virus and porcine transmissible gastroenteritis virus[J]. J Gen Virol, 100, 206-216. doi: 10.1099/jgv.0.001216
-
Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CT, Liu YF, Chen HC, Kuo CW, Wu CS, Chang LW, Chen WC, Liao SY, Chang TY, Hung HH, Shr HL, Liu CY, Huang YA, Chang LY, Hsu JC, Peters CJ, Wang AH, Hsu MC, 2006: Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor[J]. J Med Chem, 49, 4971-4980. doi: 10.1021/jm0603926
-
Yang DQ, Ge FF, Ju HB, Wang J, Liu J, Ning K, Liu PH, Zhou JP, Sun QY, 2014: Whole-genome analysis of porcine epidemic diarrhea virus (PEDV) from eastern China[J]. Arch Virol, 159, 2777-2785. doi: 10.1007/s00705-014-2102-7
-
Ye G, Deng F, Shen Z, Luo R, Zhao L, Xiao S, Fu ZF, Peng G, 2016: Structural basis for the dimerization and substrate recognition specificity of porcine epidemic diarrhea virus 3C-like protease[J]. Virology, 494, 225-235. doi: 10.1016/j.virol.2016.04.018
-
Ye G, Wang X, Tong X, Shi Y, Fu ZF, Peng G, 2020: Structural basis for inhibiting porcine epidemic diarrhea virus replication with the 3C-like protease inhibitor GC376[J]. Viruses, 12, 240-. doi: 10.3390/v12020240
-
Zhu L, George S, Schmidt MF, Al-Gharabli SI, Rademann J, Hilgenfeld R, 2011: Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease[J]. Antiviral Res, 92, 204-212. doi: 10.1016/j.antiviral.2011.08.001
-
Ziebuhr J, 2005: The coronavirus replicase[J]. Curr Top Microbiol Immunol, 287, 57-94.